November 1, 2023 by Chain Drug Review
CVS, third quarter
Featured Articles, Leading Headlines

WOONSOCKET, R.I. — CVS Health topped Wall Street’s estimates for third quarter revenue and earnings. Adjusted earnings per share of $2.21 exceeded analysts’ predicted $2.13, while revenue of $89.76 billion beat the forecast of $88.2 billion. “Our colleagues helped us deliver another quarter of positive results across our business areas,” said president and CEO Karen
November 2, 2022 by Chain Drug Review
CVS, Karen Lynch, Opioid, third quarter
Featured Articles, Leading Headlines

WOONSOCKET, R.I. — CVS Health easily beat analysts’ sales and earnings estimates for the third quarter and again raised its full year guidance. The company reported adjusted earnings per share $2.09 on revenue of $81.16 billion, which climbed 10% from a year earlier. Wall Street had expected adjusted EPS of $1.99 on revenue of $76.75
June 30, 2022 by Chain Drug Review
AllianceRx Walgreens, Brewer, third quarter, WBA
Featured Articles, Leading Headlines, Retail News

DEERFIELD, Ill. — Walgreens Boots Alliance posted third quarter sales and earnings that beat Wall Street’s projections. The company’s adjusted earnings per share of 96 cents topped analysts’ forecast of 92 cents, while its revenue of $32.6 billion exceeded the predicted $32.06 billion. WBA said it was maintaining its full year adjusted EPS guidance of
July 1, 2021 by Chain Drug Review
Brewer, third quarter, WBA
Business, Featured Articles, Leading Headlines, Retail News

DEERFIELD, Ill.— Walgreens Boots Alliance easily beat Wall Street’s estimates for third quarter sales and earnings, and raised its full year guidance. WBA’s adjusted earnings per share of $1.51 far surpassed analysts’ expectation of $1.17. Sales for the period ended May 31 rose 12.1% to $34.03 billion, topping the projected $33.76 billion. The gain reflecting
November 6, 2020 by Chain Drug Review
CVS, Merlo, third quarter
Leading Headlines, Pharmacy, Retail News

WOONSOCKET, R.I. — CVS Health’s third quarter sales and earnings beat estimates, and the company raised its full-year profit outlook, as growth in health care benefits and store sales lifted its results. Adjusted earnings for the three months ended September 30 slipped 9.8% from the year-ago period to $1.66 per share, but were still well